
LFWD Stock Forecast & Price Target
LFWD Analyst Ratings
Bulls say
Lifeward Ltd is projected to experience significant revenue growth, anticipated to rise from $29.0 million in 2025 to $336.5 million by 2032, indicating a robust revenue trajectory. This positive outlook is supported by a remarkable 86% year-over-year revenue growth, with Q4 2024 revenues reaching $7.5 million, reflecting a 23% quarter-over-quarter increase. The company's strategic partnerships and the expected launch of the next generation ReWalk 7.0 in 2025 further bolster expectations for sustained revenue growth and improved market positioning in the future.
Bears say
Lifeward Ltd is currently facing significant financial challenges, as indicated by a loss on extinguishment of debt, which suggests a deteriorating financial position and potential difficulties in managing liabilities. The absence of detailed financial performance metrics raises concerns about the company's revenue generation and growth prospects amid competitive pressure in the medical device industry. Furthermore, the lack of reported positive financial results undermines investor confidence in Lifeward's ability to sustain operations and innovate effectively in its therapeutic product offerings.
This aggregate rating is based on analysts' research of ReWalk Robotics Ltd and is not a guaranteed prediction by Public.com or investment advice.
LFWD Analyst Forecast & Price Prediction
Start investing in LFWD
Order type
Buy in
Order amount
Est. shares
0 shares